78 results
Page 3 of 4
6-K
EX-99.1
p9hfc7dd2xb1
10 Dec 20
Current report (foreign)
6:03am
6-K
EX-99.2
byl93k8
10 Dec 20
Current report (foreign)
6:03am
6-K
EX-99.1
vlrgv 41p
24 Nov 20
Current report (foreign)
6:03am
6-K
EX-1.1
a5zpv9fky2lpyx4
8 Sep 20
ObsEva Announces $20.0 Million Underwritten Offering and Concurrent Private Placement
7:40am
424B5
9czp a4giuur7z
8 Sep 20
Prospectus supplement for primary offering
7:31am
6-K
EX-99.1
jbzuy0 jk49h36hzxkj7
14 Aug 20
Current report (foreign)
4:24pm
6-K
EX-99.1
b9h2gslg
6 Aug 20
Index to Unaudited Condensed Consolidated Financial Statements
6:53am
6-K
EX-99.3
fqlyu
6 Aug 20
Index to Unaudited Condensed Consolidated Financial Statements
6:53am
6-K
EX-99.1
t0dzxuu1nybdcm16 b3
7 Jul 20
Current report (foreign)
3:39pm
6-K
EX-99.1
xdpmzvkqi
4 Jun 20
ObsEva Announces Publication of Data Showing Efficacy of Linzagolix in a Potential New Indication for Treatment of Adenomyosis
6:11am
6-K
EX-99.1
0jtb ve6e0a
5 May 20
Index to Unaudited Condensed Consolidated Financial Statements
6:01am
6-K
EX-99.3
sa6vpb0vwrho
5 May 20
Index to Unaudited Condensed Consolidated Financial Statements
6:01am
6-K
EX-99.1
m1bk8qvp
13 Nov 19
Index to Unaudited Condensed Consolidated Financial Statements
4:00pm
6-K
EX-99.3
3rndz55qw1grk7a lr4q
7 Nov 19
Current report (foreign)
9:11am
F-3
EX-4.1
ym69vf evf
7 Aug 19
Shelf registration (foreign)
8:24am
424B5
y6p6a2a rdll
7 Aug 19
Prospectus supplement for primary offering
8:18am
6-K
EX-99.1
rngsn9gae3ekq 5op
7 Aug 19
Index to Unaudited Condensed Consolidated Financial Statements
6:04am
6-K
EX-99.3
od69ns a1pni7
7 Aug 19
Index to Unaudited Condensed Consolidated Financial Statements
6:04am